Entera Bio to Present at the H.C. Wainwright 6th Annual Israel Conference
Entera Bio Ltd. (NASDAQ: ENTX) announced a virtual presentation at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) announced a virtual presentation at the H.C. Wainwright Annual Israel Conference on November 12, 2020 at 8:00 a.m. ET. The event will showcase its advancements in orally delivered large molecule therapeutics, targeting unmet medical needs in healthcare.
Entera’s proprietary technology addresses challenges in drug absorption, focusing on its lead candidates, EB613 for osteoporosis and EB612 for hypoparathyroidism, currently in Phase 2 clinical development.
Details
News Market Reaction – ENTX
The recorded move for ENTX in the trading session of this news was +1.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and JERUSALEM, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will host a virtual presentation at the H.C. Wainwright Annual Israel Conference on Thursday, November 12, 2020 at 8:00 a.m. ET.
To access a live webcast of the fireside chat on the “Investor Relations” page of Entera’s website, please click here. A replay of the webcast will be archived on Entera’s website for approximately 45 days following the presentation.
About Entera Bio
Entera is a leader in the development of orally delivered macromolecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.